Hikma Launches Nasal Naloxone Spray In US
Emergency Opioid Overdose Treatment Approved Through 505(b)(2) Pathway
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.
